AU2016215080B2 - Methods and compositions for improved cognition - Google Patents

Methods and compositions for improved cognition Download PDF

Info

Publication number
AU2016215080B2
AU2016215080B2 AU2016215080A AU2016215080A AU2016215080B2 AU 2016215080 B2 AU2016215080 B2 AU 2016215080B2 AU 2016215080 A AU2016215080 A AU 2016215080A AU 2016215080 A AU2016215080 A AU 2016215080A AU 2016215080 B2 AU2016215080 B2 AU 2016215080B2
Authority
AU
Australia
Prior art keywords
protein
klotho
seq
polypeptide
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016215080A
Other languages
English (en)
Other versions
AU2016215080A1 (en
Inventor
Dena DUBAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2016215080A1 publication Critical patent/AU2016215080A1/en
Priority to AU2020281046A priority Critical patent/AU2020281046B2/en
Application granted granted Critical
Publication of AU2016215080B2 publication Critical patent/AU2016215080B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2016215080A 2015-02-06 2016-02-05 Methods and compositions for improved cognition Active AU2016215080B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020281046A AU2020281046B2 (en) 2015-02-06 2020-12-02 Methods and compositions for improved cognition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113300P 2015-02-06 2015-02-06
US62/113,300 2015-02-06
PCT/US2016/016842 WO2016127097A1 (en) 2015-02-06 2016-02-05 Methods and compositions for improved cognition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020281046A Division AU2020281046B2 (en) 2015-02-06 2020-12-02 Methods and compositions for improved cognition

Publications (2)

Publication Number Publication Date
AU2016215080A1 AU2016215080A1 (en) 2017-08-17
AU2016215080B2 true AU2016215080B2 (en) 2020-12-24

Family

ID=56564770

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016215080A Active AU2016215080B2 (en) 2015-02-06 2016-02-05 Methods and compositions for improved cognition
AU2020281046A Active AU2020281046B2 (en) 2015-02-06 2020-12-02 Methods and compositions for improved cognition

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020281046A Active AU2020281046B2 (en) 2015-02-06 2020-12-02 Methods and compositions for improved cognition

Country Status (8)

Country Link
US (6) US10632180B2 (https=)
EP (2) EP3253403B1 (https=)
JP (1) JP6794363B2 (https=)
CN (2) CN121102455A (https=)
AU (2) AU2016215080B2 (https=)
CA (1) CA2974988A1 (https=)
HK (1) HK1246193A1 (https=)
WO (1) WO2016127097A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016215080B2 (en) 2015-02-06 2020-12-24 The Regents Of The University Of California Methods and compositions for improved cognition
EP3377091B1 (en) 2015-11-19 2023-09-20 Universitat Autònoma de Barcelona Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments
JP2018184369A (ja) * 2017-04-26 2018-11-22 株式会社明治 知的作業能力向上用組成物および認知能力向上用組成物
US12227777B2 (en) * 2018-01-12 2025-02-18 New York University Soluble alpha-Klotho proteins, protein fragments, and uses thereof
WO2019222629A1 (en) * 2018-05-17 2019-11-21 Neuralstem, Inc. Amelioration of cognitive and motor deficits associated with alzheimer's
CA3120701A1 (en) * 2018-11-21 2020-05-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for reducing age-related striated muscle and cognitive decline
EP4103223A4 (en) 2020-02-12 2024-05-29 The Regents of the University of California PLATELET FACTORS AND COGNITIVE IMPROVEMENT
US20230123357A1 (en) * 2020-03-04 2023-04-20 The Regents Of The University Of California Use of downstream factors in the klotho pathway to assess klotho activity
WO2024084400A2 (en) * 2022-10-17 2024-04-25 Bio Immunitas Ltd. Alpha 2 macroglobulin, soluble klotho and methods of use thereof
TW202434279A (zh) * 2022-10-28 2024-09-01 美商聯合生物技術公司 用於改善認知之方法
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna
CN117797249A (zh) * 2023-11-14 2024-04-02 苏州祥沁医疗科技有限公司 基于mRNA的抗衰老抗老年痴呆预防及治疗疫苗
WO2025168038A1 (en) * 2024-02-07 2025-08-14 Kunming Institute Of Zoology, Chinese Academy Of Sciences Methods and compositions for ameliorating impairment of regenerative and cognitive function

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195077A1 (en) * 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452720A (en) 1980-06-04 1984-06-05 Teijin Limited Fluorescent composition having the ability to change wavelengths of light, shaped article of said composition as a light wavelength converting element and device for converting optical energy to electrical energy using said element
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5330900A (en) 1987-12-31 1994-07-19 Tropix, Inc. Chemiluminescent 3-(substituted adamant-2'-ylidene) 1,2-dioxetanes
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
WO1998029544A1 (en) 1996-12-26 1998-07-09 Kyowa Hakko Kogyo Co., Ltd. Novel peptide, novel dna, and novel antibody
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
ATE405286T1 (de) * 2001-03-23 2008-09-15 Chemo Sero Therapeut Res Inst Neue mittel zur linderung von motorischen störungen
WO2003087768A2 (en) 2002-04-12 2003-10-23 Mitokor Targets for therapeutic intervention identified in the mitochondrial proteome
US20040001859A1 (en) 2002-06-28 2004-01-01 Cheung Ling Yuk Anti-aging dietary supplements
JP2006240990A (ja) 2003-05-15 2006-09-14 Kirin Brewery Co Ltd ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
US20100330062A1 (en) 2007-05-08 2010-12-30 Koeffler H Phillip Klotho protein and related compounds for the treatment and diagnosis of cancer
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
CN101711779B (zh) * 2008-10-08 2012-12-05 中南大学 垫状卷柏提取物在制备抗阿尔茨海默病药物中的用途
WO2011084452A1 (en) 2009-12-16 2011-07-14 Eli Lilly And Company Therapeutic uses of soluble alpha-klotho
JP2012184184A (ja) * 2011-03-04 2012-09-27 Nara Medical Univ 抗老化作用を有するヤドリギ抽出物
CN107810201A (zh) 2014-12-04 2018-03-16 诺华股份有限公司 使用klotho变体多肽的方法和组合物
AU2016215080B2 (en) 2015-02-06 2020-12-24 The Regents Of The University Of California Methods and compositions for improved cognition
EP3377091B1 (en) 2015-11-19 2023-09-20 Universitat Autònoma de Barcelona Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195077A1 (en) * 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides

Also Published As

Publication number Publication date
US10864256B2 (en) 2020-12-15
US10632180B2 (en) 2020-04-28
US10300117B2 (en) 2019-05-28
US20180015151A1 (en) 2018-01-18
AU2020281046B2 (en) 2024-04-18
US20200230214A1 (en) 2020-07-23
JP2018509393A (ja) 2018-04-05
CA2974988A1 (en) 2016-08-11
AU2020281046A1 (en) 2021-01-07
US11738070B2 (en) 2023-08-29
EP3957317A1 (en) 2022-02-23
WO2016127097A1 (en) 2016-08-11
US20240108698A1 (en) 2024-04-04
EP3253403A4 (en) 2018-09-26
JP6794363B2 (ja) 2020-12-02
US12239694B2 (en) 2025-03-04
US20250161418A1 (en) 2025-05-22
US20180256688A1 (en) 2018-09-13
CN107405382A (zh) 2017-11-28
AU2016215080A1 (en) 2017-08-17
EP3253403A1 (en) 2017-12-13
CN121102455A (zh) 2025-12-12
US20210069305A1 (en) 2021-03-11
EP3253403B1 (en) 2021-09-01
HK1246193A1 (zh) 2018-09-07

Similar Documents

Publication Publication Date Title
AU2020281046B2 (en) Methods and compositions for improved cognition
JP6000245B2 (ja) 鎮痛作用とａｓｉｃチャンネルを阻害する新規ペプチド
CN109134664A (zh) 一种经修饰的生长分化因子及其制备方法和应用
EP4103223A2 (en) Platelet factors and cognitive improvement
ES2569552T3 (es) Composiciones de péptido de MNTF y métodos de uso
KR102919967B1 (ko) 신경 가소성을 유도하기 위한 방법 및 조성물
US20230123357A1 (en) Use of downstream factors in the klotho pathway to assess klotho activity
HK40070785A (en) Methods and compositions for improved cognition
EP3920887B1 (en) A phosphatidylinositol-glycan-specific phospholipase d1 (gpld1) polypeptide for use in a method of treating or preventing age-related cognitive dysfunction
JP6987749B2 (ja) Ｓｋチャネル阻害剤による学習障害および他の神経障害の治療
WO2026059892A1 (en) Gpx3 as a blood-based calorie restriction mimetic to treat age-related cognitive decline
US20250154212A1 (en) Method of disrupting memory and lipopeptide for use in such method
WO2024092238A1 (en) Klotho polypeptide or polynucleotide for improving cognition
CN121666246A (zh) 质子泵调控剂在制备药物中的用途
WO2025002400A1 (zh) Atp6v1b2结合剂及其用途
US20140249090A1 (en) Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders
CN111588854A (zh) Trf2或其上调剂在制备治疗肌肉疾病的药物中的应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)